Quantcast

Got Stocks from QualityStocks Ones To Watch

Got Stocks

Find out which Small-Cap / Micro-Caps should be on your radar. Get the news and information that moves the markets this week and the "Ones to Watch", only at QualityStocks. The "Quality" is Back in Stocks...




Untitled Document

Vitality Biopharma, Inc. (VBIO)

Vitality Biopharma, Inc.'s commitment is to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Since 2012, Vitality has developed a unique capability for the production of molecules through glycosylation, a form of enzymatic biosynthesis, which was originally developed to improve the taste of stevia, a high-potency sweetener. The platform is well suited for the discovery of new pharmaceutical products. Vitality Biopharma has its corporate headquarters in Los Angeles, California.

Vitality Biopharma, late in 2015, successfully modified cannabidiol (CBD), which is not psychoactive, and in continuing work has created a novel class of pharmaceuticals known as cannabosides. Cannabosides, upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract. Site-specific delivery could enable oral drug formulations of cannabinoids to provide therapeutic benefits. This is while lessening or avoiding the systemic delivery of THC into the bloodstream.

The company can biosynthesize cannabinoid glycosides (cannabosides) through enzyme biosynthesis. Vitality Biopharma is one of only a very few groups around the world who know how to produce and work with the enzymes that perform glycosylation. It has been focused on it because the same enzymes are used to modify the taste of the aforementioned stevia (steviol glycosides).

Recently, Vitality Biopharma announced that it created a library of proprietary glycosides of THC (delta-9-tetrahydrocannabinol), the primary psychoactive chemical found in cannabis or marijuana that enable targeted delivery, which lessens or eliminates psychoactivity when used in oral drug formulations. The compounds are undergoing development as pharmaceuticals that enable site-specific targeting of the THC in different tissues of the body, where it can exert therapeutic effects for treatment of pain and inflammation.

Vitality Biopharma obtained DEA approval in December 2016 for its research and development facilities in California. It has now completed preclinical pharmacokinetics studies with its proprietary THC glycosides to analyze their bioavailability. Vitality has confirmed that large concentrations can be delivered orally without significant transit of THC to the brain, enabling their formulation within pharmaceuticals where drug psychoactivity will be decreased or eliminated.

Vitality Biopharma also recently announced that it has positive results indicating a new use for its proprietary prodrug cannabinoid delivery platform. Numerous colon cancer cell kinds were screened, each with unique combinations of genetic mutations that drive cancerous growth, and including a cell line known to express drug-resistance genes such as PD-L1.

Vitality Biopharma found that cannabidiol (CBD) universally inhibited cell growth at concentrations alike to established chemotherapeutics. In addition, the company found that its cannabidiol prodrug was not toxic to the human cells at the concentrations tested, demonstrating the relative safety of its prodrug delivery system.

 

 

 

The QualityStocks
Newsroom

Read the articles covering the biggest movers in the markets today.

Continue

Market
Basics

Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks markets.

Continue

The QualityStocks Daily
Archives

Go back to see our previous newsletters and find out what you might have missed.

Continue